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The evaluation of 14F7 Mab (anti-N-glycolyl GM3 ganglioside) immunorecognition in normal skin, cutaneous malignant
melanoma (CMM), and in lymph node metastases (LNM) has been previously reported. In this work we extended the study to
benign(BMN)anddysplastic(DMN)melanocyticnevi,basal(BCC),andsquamouscell carcinoma(SCC).Immunohistochemical
assays with 14F7 followed by a biotinylated link universal and streptavidin-AP in normal and pathological tissues were made. No
reaction of14F7 innormalskin(0/10)aswell as alow reactivity in BMN(2/11)andDMN (1/7)wasdetected. A limited stainingin
BCC (2/13) and in SCC (4/8) was also evidenced, while 14F7 Mab were mostly reactive in CMM (28/28) and in LNM (6/7). These
results suggest that 14F7 reactivity could be closely related with the more aggressive biological behavior of CMM and also support
the use of NeuGcGM3 as target for both passive and active melanoma immunotherapy.
1.Introduction
The incidence of human skin cancer has signiﬁcantly
increased in the last decades [1]. While basal cell carcinoma
(BCC) and squamous cell carcinoma (SCC) are malignant
neoplasms with a low lethality and a good prognosis [2],
the 10-year survival rate is 92% among the patients with T1
melanomas, and is 50% in patients with T4 melanomas [3].
Gangliosides are glycosphingolipids that contain one or
more sialic acid residues and are involved in a wide variety
of biological events that occur in the cell membranes of
vertebrates. These molecules have an important role in
tumoral progression, as well as in metastatic potential of
some malignant neoplasms [4, 5]. The events that take
place during the malignant transformation of the cells,
which lead to the establishment of qualitative and quan-
titative alterations in the gangliosides composition, have
been extensively documented [6–8]. These changes allow
considering some gangliosides as tumor-associated antigens
and they have been selected as possible target for active and
passive immunotherapy [9, 10]. The aberrant expression of
N-glycosylated gangliosides has been identiﬁed in several
malignancies using immunohistochemical methods [10, 11].
The N-glycolyl GM3 ganglioside (NeuGcGM3) expres-
sion in cutaneous melanoma and breast ductal carcinoma
using 14F7 Mab, as well as its limited presence in normal
adult human tissues was previously reported by our group
[10]. More recently, the study was extended to cutaneous
melanomas and their metastases [12]a n dt oe p i t h e l i a l
tumors of the digestive system [13]. Additionally, the expres-
sion of NeuGcGM3 in nonsmall cell lung cancer as well as in
Wilms tumor has been also reported [14, 15].
The analysis of 14F7 Mab immunoreactivity could be
useful in order to extend the assessment of this molecule
as target for cancer immunotherapy as well as to look for
a better understanding of the diﬀerences in the biological2 ISRN Dermatology
behavior of the primary malignancies of the human skin.
Here we show the evaluation of the 14F7 Mab recognition
in other benign and malignant entities of human skin such
as benign (BMN) and dysplastic melanocytic nevi (DMN),
BCC, and SCC. CMM, lymph node metastases and samples
of normal skin were also included in the study.
2.Materialsand Methods
2.1. Monoclonal Antibody. We used 14F7 Mab, produced at
the Center of Molecular Immunology (Havana, Cuba) as
previously described [10].
2.2. Tissue Specimens. Ten normal skin samples, 11 benign
melanocytic nevi, 7 dysplastic nevi, 8 squamous cell carci-
nomas, 13 basal cell carcinomas, 28 cutaneous melanomas,
and 7 lymph node metastases formalin-ﬁxed and paraﬃn
embedded tissues from Manuel Fajardo General Hospital
and the National Institute of Oncology and Radiobiology
were obtained, after approved consent by the institutional
ethical committees.
2.3.ImmunohistochemicalProcedure. Fivemicronsectionsof
formalin-ﬁxed and paraﬃn-embedded tissues were obtained
in a microtome (Leitz 1512). The samples were kept at 70◦C
for 1h, dewaxed and rehydrated in a descending ethanol
seriesandkeptindistilled waterfor10minutes andthenTBS
solutionfor5 minutes. Afterward thereactivity oftotaltissue
proteins was blocked with a commercial solution (Dako
X0909, Carpinteria, USA) for 10 minutes as described [13].
T h es l i d e sw e r ei n c u b a t e dw i t h1 4 F 7M a b( 1 0µg/mL) for 1h
in humid chamber, then incubated with a biotinylated link
universal and streptavidin-AP (Dako K0678, Carpinteria,
USA) for 30 minutes each step. Replacement of 14F7 by
TBS and a sample of breast inﬁltrating ductal carcinoma
[10] were used as negative and positive controls, respectively.
Between incubations the samples were washed with TBS
for 10 minutes. The enzyme activity was detected with a
commercial solution of fuchsin (a red chromogen) (Dako
K0678, Carpinteria, USA) in order to avoid confusion with
melanin. Afterward, the tissues were counterstained with
Mayer’s Hematoxylin (Dako S2020, Carpinteria, USA) and
the slides were mounted with aqueous mounting medium
(Dako S3025, Carpinteria, USA).
2.4. Evaluation of Results. The intensity of the reaction was
qualitatively estimated and expressed as follows: negative
(−), weak (+), moderate (++), and intense (+++) and com-
binations of these patterns were used to express intermediate
levelsofexpression. The percentagesofimmunoreactive cells
(positive cells) were estimated in the most representative
areasoftumorswitha10Xlensandscoredfrom0to3,where
0 represents the absent of immunostaining (negative up to
5%), 1 (6–25%), 2 (26–50 %) and 3 (more than 50%) of the
cells exhibiting staining. The results of two observers were
considered as the ﬁnal evaluation.
3.Results
3.1. Immunohistochemical Staining in Normal and Nonma-
lignant Lesions of Human Skin. The results of 14F7 Mab
immunoreactivity in some normal and nonmalignant for-
malin-ﬁxed and paraﬃn-embedded human skin samples are
showed in Table 1.
3.2. Normal Skin. No immunorecognition of 14F7 Mab in
normal melanocytes and keratinocytes (0/10) was observed.
3.3. Benign and Dysplastic Melanocytic Nevi. The 14F7
immunostaining was observed in 2/11 (18.2%) of benign
melanocytic nevi. A weak to moderate reaction following a
homogeneous and ﬁnely granular pattern in 2/6 (33.3%) of
compoundneviwasdetected.Thisrecognitionwaslocatedin
the plasmatic membrane and also in the cytoplasm of more
than 50% of melanocytes (Figure 1). No immunoreaction
in melanocytes from others benign nevi such as intradermic
(0/4), and junctional (0/1) was observed.
A weak immunorecognition of 14F7 Mab in 1/7 (14.3%)
of dysplastic melanocytic nevi was evidenced. The staining
was located mainly in the plasmatic membrane and also in
the cytoplasm of melanocytes (data no shown). When the
number of positive samples, the intensity range of reaction,
and the percentages of positive cells in BMN versus DMN
were compared, no statistically signiﬁcant diﬀerences were
observed (P = .1851 by Fisher’s Exact Test, P = .4150, and
P = .4731 by chi-square Test, resp.).
3.4.ImmunohistochemicalStaining in SomeMalignant Tissues
from Human Skin. Table 2 shows the results of 14F7 Mab
immunoreaction in some malignancies derived from human
skin.
3.5. Basal Cell Carcinoma. A weak to moderate staining
with 14F7 Mab in 2/13 (15.4%) of basal cell carcinoma
was observed. This recognition was evidenced homogeneous
and ﬁnely granular and was located mainly in the plasmatic
membrane and also in the cytoplasm of malignant ker-
atinocytes. This patternwas describedmostly in thecenterof
the typical lobules and columns of malignant basaloid cells
(Figure 2).
3.6. Squamous Cell Carcinoma. A weak to intense immunos-
taining in more than 5% of tumoral cells in 4/8 (50%)
of squamous cell carcinomas was evidenced. The immun-
orecognition of 14F7 was homogeneous and ﬁnely granular
and was located in the membrane and the cytoplasm of
malignant keratinocytes. Two of these samples showed a
weak reaction in 5% of tumor cells, while an intense staining
was observed in 30–40% of these malignant cells from the
rest of the positive tumors. The reactivity of 14F7 Mab
became more intense near the central keratinization and
horn pearl formation (Figure 2)i nt h el a s tt w os a m p l e s .
No statistically signiﬁcant diﬀerences in the 14F7 reac-
tion was detected when the number of positive samples inISRN Dermatology 3
Table 1: Immunorecognition of 14F7 Mab in normaland non-malignantlesions of humanskin.
Samples No. cases (%) Range intensity Positive cells
(i) Normalskin 0/9 (0) − 0
(ii) Nevi
Benign melanocytic nevi 2/11 (18,2) +/ ++ 3
Dermal 0/4 (0) − 0
Junctional 0/1 (0) − 0
Compound 2/6 (33,3) +/ ++ 3
Displastic melanocytic nevi 1/7 (14,3) + 1
Intensity: − negative, + weak, ++ moderate, +++ intense. Positive cells: 0 (negative to less than 5%), 1 (6–25%), 2 (26–50%) and 3 (more than 50%).
Table 2: Immunorecognition of 14F7 Mab in malignantlesions derived from human skin.
Samples No. cases (%) Range intensity Positive cells
(i) Nonmelanomaskin tumors
Basal cell carcinoma 2/13 (15.4) +/ ++ 1
Solid 0/7 − 0
Adenoid 2/5 (40) +/ ++ 1
Keratotic 0/1 − 0
Squamous cell carcinoma 4/8 (50) +/ ++ + 1/2
Well diﬀerentiated 2/6 (33.3) +++ 2
Ulcerated 2/2 + 1
(ii) Cutaneous malignantmelanoma 28/28 (100) +++ 3
Melanotic 27/27 +++ 3
A me lanot ic 1/1 +++ 3
(iii) Lymph node metastases 6/7 (85.7) ++/ ++ + 1/3
Intensity: − negative, + weak, ++ moderate, +++ intense. Positive cells: 0 (negative to less than 5%), 1 (6–25%), 2 (26–50%) and 3 (more than 50%).
BCCversusSCCwere compared(P = .1006byFisher’s Exact
Test), neither when the intensity range of reaction and the
percentages of positive cells were analyzed (P = .0920 and
P = .3062 by chi-square Test, resp.).
3.7. Cutaneous Malignant Melanoma. An intense homoge-
neous and ﬁnely granular pattern of recognition was present
in all CMM tested (28/28), 27 of which were melanotic and
1, amelanotic (Figure 3). The reaction was located mainly
on the plasmatic membrane in more than 50% of malignant
melanocytes, although the cytoplasm of these cells was also
stained.
The immunoreactivity of 14F7 Mab show a statistically
signiﬁcant diﬀerences when BMN + DMN versus CMM and
when BCC + SCC versus CMM were compared in function
of all parameters measured (P = .0000 by Fisher’s Exact Test
and by chi-square Test).
3.8. Lymph Node Metastases. A moderate to intense reac-
tivity of 14F7 Mab was detected in more than 50% of
tumoral cells in 5/7 (71.4%) of lymph node metastases. The
recognition of 14F7 was homogeneous and ﬁnely granular
and was located in the membrane and the cytoplasm of
malignant melanocytes (Figure 3). A heterogeneous pattern
was evidencedin one sample, exhibiting a moderate reaction
with 14F7 in 6–25% of malignant cells.
No statistically signiﬁcant diﬀerent in CMM versus LNM
was evidenced when the number of positive sample was
analyzed (P = .2059 by Fisher’s Exact Test). On the contrary,
when the intensity range of reaction and the percentages
of positive cells were compared, statistically signiﬁcant
diﬀerences were detected (P = .0002 and P = .0166 by chi-
square Test, resp.).
4.Discussion
Gangliosides are glycosphingolipids containing sialic acid,
widely distributed in human tissues of both normal and
tumoral neuroectodermal origin [4, 16]. These molecules
have been considered attractive targets for cancer immun-
otherapy and diagnosis based on their higher expression in
tumors as compared with normal tissues, as well as, their
relevance in tumoral growth [9].
It is known that GM3, GM2, and GD3 are the pre-
dominant gangliosides in most of the samples of normal
keratinocytes, although immunohistochemical studies using
anti-GM3 (M2590) and anti-GD3 (R24) monoclonal anti-
bodies showed a just weak recognition of these cells. Similar
results were obtained in squamous cell carcinoma and basal
cell carcinoma of human skin [17]. Additionally, the expres-
sion of 9-O-Ac-GD3 ganglioside, not expressed in normal
keratinocytes, was detected in basal cell carcinoma [18].4 ISRN Dermatology
(a) (b)
Figure 1: Hematoxylin and eosin staining of benign melanocytic nevi (a). Immunorecognition of 14F7 Mab (b). Note that a weak to
moderate (ﬁnely granular) reactivity located on plasmatic membrane and cytoplasm of nevi cells. Black bar = 100µm.
(a) (b)
(c) (d)
Figure 2: Hematoxylin and eosin staining of basal cell carcinoma (a) and squamous cell carcinoma of human skin (c). A moderate
immunostaining with 14F7Mab was detected on basal cell carcinoma mostly located in the center of the typical lobules and columns
of malignant basaloid cells (b). The squamous cell carcinoma showed an intense reaction becoming into more intense near the central
keratinizationand horn pearl formation (d). Black bar =100µm.ISRN Dermatology 5
(a) (b)
(c) (d)
Figure 3: Hematoxylin and eosin staining of cutaneous malignant melanoma (a) and lymph node metastase (c). See a strong and ﬁnely
granular immunoreactivity of 14F7Mab in cutaneous malignant melanoma (b) as well as, in lymph node metastases (d). The reaction was
located on plasmatic membrane and cytoplasm. Black bar =100µm.
On the other hand, the expression of little amounts of N-
glycolyl neuraminic acid in this malignant neoplasm has
been also reported [19]. In addition, gangliosides are shed
in substantial quantities into the tumor microenvironment.
Afterward, they are taken up and bnd eﬃciently to host cells
that are found in this microenvironment [20].
N-glycolyl neuraminic acid has been considered to be
absent in normal human tissues [21]duetoa partial deletion
of the gene coding for the production of CMP-Neu5Ac
hydroxylase [22], although the expression of N-glycolyl
gangliosides has been reported in various malignancies [8,
10, 11, 23]. The expression of N-glycolyl neuraminic acid
residues in neoplastic cells has been associated with its
incorporation, by mean of dietary sources, to the accelerated
metabolism of these cells [24, 25]. Moreover, some authors
havesuggested an alternative pathway to the Neu5Gcsynthe-
sis from others intermediates of cellular metabolism in some
human tumors [26].
In our study, we conﬁrmed the lack of reactivity of 14F7
Mab in normal skin samples as we previously published
[10]. This result is consistent with the absence of N-glycolyl
function in normal keratinocytes [27]. It is known that GM3
ganglioside is a normal component of plasmatic membrane
ofnormal human cells[28],includingkeratinocytes[17, 29].
Therefore, we also conﬁrmed that 14F7 is able to distinguish
between the N-glycolyl and the N-acetyl functions of the
GM3 ganglioside [10].
BCC and SCC are malignant neoplasms arising from the
keratinocytes, cells of ectodermal origin that usually show
a slower and less invasive cellular growth than CMM [2].
Nevertheless, it is known that some SCC can be biologically
aggressive, showing a greater propensity for local recurrence
and metastatic potential [30], while most of BCC are less
aggressive than SSC and their prognosis is very good [2].
Here we described a low recognition of 14F7 in BCC and
SCC. These results are in agreement with the lack of recogni-
tion of P3 Mab in BCC and SCC (a murine Mab speciﬁc for
N-glycolylneuraminic acid-containing gangliosides that also
recognizes sulfated glycolipids) [11], as well as with previous
reports of Carr et al. in epidermoid carcinoma using 14F7
MAb [10].
The tissue oxygen content changes gradually with dis-
tance from blood vessels as occurs in SCC [31]. The
inﬂuence of tumor hypoxia in the formation, progression
and evolution of cutaneous melanoma to a more aggressive
formofthedisease hasbeenpreviouslyreported[31].Tumor6 ISRN Dermatology
hypoxia induces the expression of NeuGcGM2 gangliosides
in human cancer cells through the incorporation of the
nonhuman sialic acid NeuGc, supporting the idea that the
speciﬁc eﬀect of hypoxia is to expedite sialic acid transport
from the external medium, in relation with the increment
of sialin expression (a sialic acid transport) [32]. The 14F7
immunoreactivity mainly located in the center of the typical
lobules and columns of malignant basaloid cells and close to
the central keratinization and horn pearl formation in two
of SCC could suggest a higher expression of NeuGc function
in these areas as well as a possible relationship with tumor
hypoxia.
It is well known that melanoma is a malignant neoplasm
arising from the melanocytes, cells of neuro-ectodermal
origin, which show a very aggressive biological behavior
and poor prognosis [3]. Numerous eﬀorts have been done
to demonstrate the relationship between melanocytic nevi
and malignant melanoma. In addition, some immunohis-
tochemical methods have been used to distinguish between
normal skin, melanocytic nevi, and primary melanoma,
based in some changes in expression and/or composition of
gangliosides [16, 33–35].
Some author have reported aberrant expression of gan-
gliosidos in melanocytes neoplasias [16, 33, 35, 36].
Although the major gangliosides expression studies in
human malignancies have been restricted to N-acetylated
variantofsialicacid[33,34,36].Hanganutziu-Deicher(HD)
antigens have been reported to be absent in normal human
tissues and melanocytic nevus, but can be expressed on
a variety of human malignant cells, including melanoma
[27, 37, 38] .H Da n t i g e ni sc l a s s i ﬁ e da sah e t e r o p h i l ea n t i g e n
and chemically deﬁned as a ganglioside and/or glycoprotein
(glycoconjugates) which contains N-glycolylneuraminic acid
(NeuGc) [37]. Here we obtained a low immunostaining in
B M Na sw e l la si nD M N .
All CMM studied and lymph node metastases reacted
intensely with the 14F7. The immunostaining pattern was
similar to previous reports from our group [10, 12].
However, Kawachi and Saida suggested that HD antigen is
expressed on the carbohydrate chains of glycoproteins but
not on those of gangliosides in human melanoma [39]. It
is known glycolipids are partially or completely extracted
from the tissues after ethanol and absolute methanol
treatment. Additionally, gangliosides are lowly expressed in
human skin and they represent only the 0.1 percent of the
epidermal lipids [40]. These results suggest that probably
14F7 Mab cross-reacts with other glycoconjugate containing
NeuGc.
In summary, we reported an intense recognition of
14F7 Mab in cutaneous melanomas and lymph nodes
metastases, while, the rest of the entities showed a limited
reaction. These results suggest that 14F7 reactivity could be
closely related with the more aggressive biological behavior
of melanocytes-derived tumors. Experiments looking for
a better understanding of the 14F7 recognition and its
relationship with the biological behavior of these malignant
tumors, as well as, for the evaluation of the chemical nature
of the antigenic determinant recognized by 14F7Mab are
ongoing. In addition, clinical trials with NeuGcGM3/VSSP
molecular cancer vaccine in melanoma patients are ongoing
in our country.
5.Conclusions
The recognition of 14F7Mab in cutaneous malignant mel-
anoma and lymph node metastases as well as its limited
reaction in normal sections and other entities of human skin
suggests a possible relationship between the 14F7 reactivity
with the more aggressive behavior of malignant tumor of
melanocytes. Our data could support the possible use of
NeuGcGM3 as target for both active and passive immun-
otherapy of malignant melanoma expressing this molecule.
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